文献リスト

1）泉　並木，玉城信治．肝硬変の成因別実態 2014 全国の集計．肝硬変の成因別実態．2014; 2015; 1-3

2）Sakaida I, Nakajima K, Okita K, et al. Can serum albumin level affect the pharmacological action of tolvaptan in patients with liver cirrhosis? A post hoc analysis of previous clinical trials in Japan. J Gastroenterol. 2015 Feb 18. [Epub ahead of print]

3）Goto A, Terai S, Nakamura M, et al. Re-response to tolvaptan after furosemide dose reduction in a patient with refractory ascites. Clin J Gastroenterol. 2015; 8: 47-51

4）Jiang Q, Jiang G, Shi KQ, et al. Oral aetyl-L-carnitine treatment in hepatic encephalopathy: view of evidence-based medicine. Ann Hepatol. 2013; 12: 803-9

5）Hirano H, Saito M, Yano Y, et al. Chronic liver disease questionnaire would be a primary screening tool of neuropsychiatric test detecting minimal hepatic encephalopathy of cirrhotic patients. Hepatol Res. 2015 Jul 31. [Epub ahead of print]

6）Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010; 362: 1071-81

7）Cheung K, Lee SS, Raman M. Prevalence and mechanisms of malnutrition in patients with advanced liver disease, and nutrition management strategies. Clin Gastroenterol Hepatol. 2012; 10: 117-25

8）Sakai Y, Iwata Y, Enomoto H, et al. Two randomized controlled studies comparing the nutritional benefits of branched-chain amino acid (BCAA) granules and a BCAA-enriched nutrient mixture for patients with esophageal varices after endoscopic treatment. J Gastroenterol. 2015; 50: 109-18

9）Demiroren K, Dogan Y, Kocamaz H, et al. Protective effects of L-carnitine, N-acetylcysteine and genistein in an experimental model of liver fibrosis. Clin Res Hepatol Gastroenterol. 2014; 38: 63-72

10）Toshikuni N, Arisawa T, Tsutsumi M, et al. Nutrition and exercise in the management of liver cirrhosis. World J Gastroenterol. 2014; 20: 7286-97

11）Okita K, Izumi N, Ikeda K, et al. Survey of survival among patients with hepatitis C virus-related hepatocellular carcinoma treated with peretinoin, an acyclic retinoid, after the completion of a randomized, placebo-controlled trial. J Gastroenterol. 2015; 50: 667-74

12）Okita K, Izumi N, Matsui O, et al. Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study. J Gastroenterol. 2015; 50: 191-202

13）Bhat A, Sebastiani G, Bhat M. Systematic review: Preventive and therapeutic applications of metformin in liver disease. World J Hepatol. 2015; 7: 1652-9

14）Morrison MC, Kleemann R. Role of macrophage migration inhibitory factor in obesity, insulin resistance, type 2 diabetes, and associated hepatic co-morbidities: A Comprehensive Review of Human and Rodent Studies. Front Immunol. 2015; 6: 308

15）Moreira de Macêdo S, Guimarães TA, Feltenberger JD, et al. The role of renin-angiotensin system modulation on treatment and prevention of liver diseases. Peptides. 2014; 62: 189-96

16）Kirpich IA, Marsano LS, McClain CJ. Gut-liver axis, nutrition, and non-alcoholic fatty liver disease. Clin Biochem. 2015 Jul 4. [Epub ahead of print] Review

17）Tatsumi A, Maekawa S, Sato M, et al. Liver stiffness measurement for risk assessment of hepatocellular carcinoma. Hepatology Res. 2015; 45: 523-32

18）Ferraioli G, Parekh P, Levitov AB, et al. Shear Wave Elastography for Evaluation of Liver Fibrosis. J Ultrasound Med. 2014; 33: 197-203

19）Procopet B, Berzigotti A, Abraldes JG, et al. Real-time shear-wave elastography: Applicability, reliability and accuracy for clinically significant portal hypertension. J Hepatology. 2015: 62; 1068-75

20）Kuno A, Ikehara Y, Tanaka Y, et al. A serum "sweet-doughnut" protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. Sci Rep. 2013; 3: 1065

21）Yamasaki K, Tateyama M, Abiru S, et al. Elevated serum levels of Wisteria floribunda agglutinin-positive human Mac-2 binding protein predict the development of hepatocellular carcinoma in hepatitis C patients. Hepatology. 2014; 60: 1563-70

22）Toyoda H, Kumada T, Tada T, et al. Serum WFA+ -M2BP levels as a prognostic factor in patients with early hepatocellular carcinoma undergoing curative resection. Liver Int. 2015 Jul 2. [Epub ahead of print]

23）Ahluwalia V, Heuman DM, Feldman G, et al. Correction of hyponatraemia improves cognition, quality of life, and brain oedema in cirrhosis. J Hepatol. 2015; 62: 75-82

24）Sakaida I, Kawazoe S, Kajimura K, et al. Tolvaptan for improvement of hepatic edema: A phase 3, multicenter, randomized, double-blind, placebo-controlled trial. Hepatol Res. 2014; 44: 73-82

25）Imamura T, Kinugawa K, Shiga T, et al. Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients -association between non-responders and chronic kidney diseases. Circ J. 2013; 77: 397-404

26）Imamura T, Kinugawa K, Fujino T, et al. Increased urine aquaporin-2 relative to plasma arginine vasopressin is a novel marker of response to Tolvaptan in patients with decompensated heart failure. Circ J. 2014; 78: 2240-49

27）森　建文，小泉賢治，佐藤真一，他．肝硬変に対する利尿薬治療における腎生理．Fluid Management Renaissance. 2014; 4: 37-46

28）Saito M, Hirano H, Yano Y, et al. Serum level of taurine would be associated with the amelioration of minimal hepatic encephalopathy in cirrhotic patients. Hepatol Res. 2015 Jul 29. [Epub ahead of print]

29）Nakanisi H, Kurosaki M, Tsuchiya K, et al. L-carnitine Reduces Muscle Cramps in Patients With Cirrhosis. Clin Gastroenterol Hepatol. 2015; 13: 1540-3

30）Iritani S, Imai K, Takai K, et al. Skeletal muscle depletion is an independent prognostic factor for hepatocellular carcinoma. J Gastroenterol. 2015; 50: 323-32

31）Kamachi S, Mizuta T, Otsuka T, et al. Sarcopenia is a risk factor for the recurrence of hepatocellular carcinoma after curative treatment. Hepatol Res. 2015 Jul. [Epub ahead of print]

32）Hanai T, Shiraki M, Nishimura K, et al. Sarcopenia impairs prognosis of patients with liver cirrhosis. Nutrition. 2015; 31: 193-9

33）Tsien C, Davuluri G, Singh D, et al. Metabolic and molecular responses to leucine-enriched branched chain amino acid supplementation in the skeletal muscle of alcoholic cirrhosis. Hepatology. 2015; 61: 2018-29

34）Kawaguchi T, Nagao Y, Abe K, et al. Effects of branched-chain amino acids and zinc-enriched nutrients on prognosticators in HCV-infected patients: a multicenter randomized controlled trial. Mol Med Rep. 2015; 11: 2159-66

35）Okita K, Izumi N, Ikeda K, et al. Survey of survival among patients with hepatitis C virus-related hepatocellular carcinoma treated with peretinoin, an acyclic retinoid, after the completion of a randomized, placebo-controlled trial. J Gastroenterol. 2015; 50: 667-74

36）Okita K, Izumi N, Matsui O, et al. Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study. J Gastroenterol. 2015; 50: 191-202

37）Seki E, De Minicis S, Osterreicher CH, et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med. 2007; 13: 1324-32

38）Douhara A, Moriya K, Yoshiji H, et al. Reduction of endotoxin attenuates liver fibrosis through suppression of hepatic stellate cell activation and remission of intestinal permeability in a rat non-alcoholic steatohepatitis model. Mol Med Rep. 2015; 11: 1693-700

39）Imajo K, Fujita K, Yoneda M, et al. Hyperresponsivity to Low-Dose Endotoxin during Progression to Nonalcoholic Steatohepatitis Is Regulated by Leptin-Mediated Signaling. Cell Metab. 2012; 16: 44-54

40）Aihara Y, Yoshiji H, Noguchi R, et al. Direct renin inhibitor, aliskiren, attenuates the progression of non-alcoholic steatohepatitis in the rat model. Hepatol Res. 2013; 43: 1241-50

41）Yoshiji H, Noguchi R, Namisaki T, et al. Combination of sorafenib and angiotensin-II receptor blocker attenuates preneoplastic lesion development in a non-diabetic rat model of steatohepatitis. J Gastroenterol. 2014; 49: 1421-9

42）Namisaki T, Noguchi R, Moriya K, et al. Beneficial effects of combined ursodeoxycholic acid and angiotensin-II type 1 receptor blocker on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis. J Gastroenterol. 2015. Jul 21. [Epub ahead of print]

43）Noguchi R, Yoshiji H, Ikenaka Y, et al. Dual blockade of angiotensin-II and aldosterone suppresses the progression of a non-diabetic rat model of steatohepatitis. Hepatol Res. 2013; 43: 765-74

44）Niwa Y, Ishikawa K, Ishigami M, et al. Effect of hyperglycemia on hepatocellular carcinoma development in diabetes. Biochem Biophys Res Commun. 2015; 463: 344-50

45）Umemura A, Park EJ, Taniguchi K, et al. Liver damage, inflammation, and enhanced tumorigenesis after persistent mTORC1 inhibition. Cell Metab. 2014; 20: 133-44

46）Sumie S, Kawaguchi T, Kawaguchi A, et al. Effect of pioglitazone on outcome following curative treatment for hepatocellular carcinoma in patients with hepatitis C virus infection: A prospective study. Mol Clin Oncol. 2015; 3: 115-20

47）Tomita K, Teratani T, Suzuki T, et al. Acyl-CoA: cholesterol acyltransferase 1 mediates liver fibrosis by regulating free cholesterol accumulation in hepatic stellate cells. J Hepatol. 2014; 61: 98-106

48）Sato Y, Murase K, Kato J, et al. Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone. Nat Biotechnol. 2008; 26: 431-42

49）Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015; 385: 956-65

50）Okusaka T, Aramaki T, Inaba Y, et al. Phase I study of tivantinib in Japanese patients with advanced hepatocellular carcinoma: Distinctive pharmacokinetic profiles from other solid tumors. Cancer Sci. 2015; 106: 611-7

51）El-Khoueiry AB, Melero I, Crocenzi TS, et al. Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040. J Clin Oncol. 2015; 33, suppl abstr. : LBA101

52）寺井　崇，坂井田功．自己骨髄細胞投与による肝再生，修復治療．生化学．2012; 84: 707-11

53）Nakamura T, Tsutsumi V, Torimura T, et al. Human peripheral blood CD34-positive cells enhance therapeutic regeneration of chronically injured liver in nude rats. J Cell Physiol. 2012; 227: 1538-52

54）中村　徹，古賀浩徳，池園　友，他．生体外増幅CD34＋細胞移植による肝再生治療に対するintegrin αvβ3の重要性. 肝臓. 2015; 56 supple 1: A344

55）Takebe T, Sekine K, Enomura M, et al. Vascularized and functional human liver from an iPSC-derived organ bud transplant. Nature. 2013; 499: 481-4

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp